icatibant: Clinical Trials

9 trials of icatibant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 active not recruiting, 1 withdrawn. 9 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 7, Active not recruiting 1, Withdrawn 1
Phase 32Completed 2

Follow icatibant: new trials by email Literature Review of icatibant trials Research Report on icatibant

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Inhibition of Bradykinin in COVID-19 Infection With Icatibant
Icatibant, 0.9% Sodium Chloride Injection - SARS CoV 2 Infection
Phase 2 / Phase 3CompletedBelfast Health and Social Care Trust322022-05-162023-09-07
Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection
Firazyr, SoC - COVID-19 Pneumonia
Phase 2CompletedSebastian Videla732021-04-122022-08-03
Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).
C1 Inhibitor Human, Icatibant Injection, Placebo - Covid19
Phase 2CompletedGCS Ramsay Santé pour l'Enseignement et la Recherche442021-02-042022-12-22
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Remdesivir, Imatinib Mesylate, Dexamethasone - COVID-19
Phase 2Active not recruitingQuantumLeap Healthcare Collaborative15002020-07-312026-03-16
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid - Heart Failure NYHA Class I, Heart Failure NYHA Class II
Phase 2WithdrawnVanderbilt University Medical Center2017-09-012018-01-11
Mitochondria and Chronic Kidney Disease
Icatibant, Placebo - Hemodialysis-Induced Symptom, Mitochondrial Diseases
Phase 2CompletedVanderbilt University Medical Center112017-08-012019-10-29
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass
HOE 140, Aminocaproic Acid, Placebo - Cardiopulmonary Bypass, Inflammation
Phase 2 / Phase 3CompletedVanderbilt University1502006-05-012013-11-25
Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis
HOE140 Icatibant - Joint Disease
Phase 2CompletedSanofi5902006-02-012012-02-17
AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study
Icatibant (subcutaneous) and plazebo (intravenous), Cortisone + Clemastin (intravenous) and plazebo (subcutaneous) - Angioedema
Phase 2CompletedTechnical University of Munich2011-12-23

Conditions studied

COVID-19 (3)  ·  Angioedema (1)  ·  Disease (1)  ·  Inflammation (1)  ·  Joint Diseases (1)  ·  Mitochondrial Diseases (1)  ·  Osteoarthritis (1)  ·  Respiratory Distress Syndrome (1)  ·  Respiratory Insufficiency (1)

Sponsors

Vanderbilt University Medical Center (2)  ·  Belfast Health and Social Care Trust (1)  ·  GCS Ramsay Santé pour l'Enseignement et la Recherche (1)  ·  QuantumLeap Healthcare Collaborative (1)  ·  Sanofi (1)  ·  Sebastian Videla (1)  ·  Technical University of Munich (1)  ·  Vanderbilt University (1)

Countries

United States (5)  ·  Germany (2)  ·  Austria (1)  ·  Czechia (1)  ·  France (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Derek W Russell, MD (1)  ·  Joe Kidney, MD (1)  ·  Kathleen D Liu, MD (1)  ·  Laura Esserman, MD (1)  ·  Mias Pretorius, MBChB (1)  ·  Murat Bas, Dr. (1)

Results publications

PMID 23361105, PMID 25629740, PMID 34473343, PMID 35413921, PMID 36610464, PMID 36883141, PMID 38035747, PMID 39592213, PMID 40462830, PMID 42799508